Key facts
- It has raised $4.9M across 1 recorded rounds; the latest was Merger/Acquisition in Jan 2026.
- Grove AI has filed 1 Form D with the SEC, most recently Jan 2025 ($4.9M sold to 14 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Grove AI
Funding rounds
1 roundsAbout Grove AI
Developer of a clinical trial management platform intended to enhance participant engagement and streamline trial processes. The company offers a platform that facilitates efficient participant interactions, manages in-person appointments, and reduces manual workflow hours, enabling clinical research organizations and pharmaceutical sponsors to optimize trial operations while improving participant screening and response times.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 10
- Website
- grovetrials.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Grove AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Grove AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Grove AI in its N-PORT filings yet. We sweep new filings monthly.